Analyst Price Target is $34.00
▲ +194.37% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Arcellx in the last 3 months. The average price target is $34.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 194.37% upside from the last price of $11.55.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Arcellx.
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.